Controlling Shareholder Sells 80% Stake Amidst Going Concern Warning and Zero Revenue

summarizeSummary

BIOFORCE NANOSCIENCES HOLDINGS, INC. reported continued zero revenue, a going concern warning, and material weaknesses, with its Chairman selling an 80% controlling stake post-quarter.

check_boxKey Events

• Controlling Interest Sold

  Chairman Merle Ferguson sold his approximately 80% controlling stock interest in a private transaction to Nexus Capital Investments, Inc. on April 15, 2026. This represents a significant change in ownership and control.

• Going Concern Warning

  The company continues to report recurring losses, net current liabilities, and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern. Cash on hand is minimal at $6,347.

• Zero Revenue & Increased Liabilities

  For Q1 2026, the company reported zero revenue and an increased total liabilities of $727,301, up from $619,329 at year-end 2025.

• Material Weaknesses in Internal Controls

  Management identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties and a lack of review in the financial reporting process.

auto_awesomeAnalysis

This quarterly report reveals a company in severe financial distress, marked by zero revenue, recurring losses, and a critical "going concern" warning. The most significant development is the post-quarter sale of an 80% controlling interest by Chairman Merle Ferguson to Nexus Capital Investments, Inc. This change of control, coupled with the company's precarious financial state and disclosed material weaknesses in internal controls, indicates a fundamental shift and raises serious questions about its future viability. While Ferguson also forgave accrued compensation, this is heavily overshadowed by the controlling stake sale.